Compare FLGC & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLGC | TOVX |
|---|---|---|
| Founded | 2019 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 7.3M |
| IPO Year | 2021 | 2006 |
| Metric | FLGC | TOVX |
|---|---|---|
| Price | $10.31 | $0.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.3K | ★ 2.5M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,609,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.71 | N/A |
| 52 Week Low | $6.80 | $0.20 |
| 52 Week High | $81.90 | $2.08 |
| Indicator | FLGC | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 44.00 |
| Support Level | $9.28 | $0.21 |
| Resistance Level | $11.22 | $0.25 |
| Average True Range (ATR) | 1.29 | 0.03 |
| MACD | 0.48 | 0.00 |
| Stochastic Oscillator | 45.75 | 41.01 |
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.